SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Steen V) "

Sökning: WFRF:(Steen V)

  • Resultat 121-130 av 131
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
121.
  •  
122.
  •  
123.
  •  
124.
  •  
125.
  • Tritsaris, Katerina, et al. (författare)
  • IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs
  • 2007
  • Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 104:39, s. 15364-15369
  • Tidskriftsartikel (refereegranskat)abstract
    • Successful therapeutic angiogenesis for the treatment of ischemic disorders relies on selection of optimal proangiogenic or arteriogenic agents that are able to promote establishment of functional collateral networks. Here, we show that IL-20, a pleiotropic inflammatory cytokine, displays an imperative effect on vascular remodeling. Stimulation of both large and microvascular endothelial cells with IL-20 leads to activation of receptor-dependent multiple intracellular signaling components, including increased phosphorylation levels of JAK2/STAT5, Erk1/2, and Akt; activation of small GTP-binding proteins Rac and Rho; and intracellular release of calcium. Surprisingly, IL-20 significantly promotes endothelial cell tube formation without affecting their proliferation and motility. These findings suggest that the vascular function of IL-20 involves endothelial cell organization, vessel maturation, and remodeling. Consistent with this notion, delivery of IL-20 to the ischemic muscle tissue significantly improves arteriogenesis and blood perfusion in a rat hind-limb model. Our findings provide mechanistic insights on vascular functions of IL-20 and define therapeutic implication of this cytokine for the treatment of ischemic disorders.
  •  
126.
  •  
127.
  •  
128.
  • Wallentin, Lars, et al. (författare)
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation
  • 2013
  • Ingår i: Circulation. - 0009-7322 .- 1524-4539. ; 127:22, s. 2166-2176
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundIn the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).Methods and ResultsThe trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 months. For each patient, a center average TTR was estimated with the use of a linear mixed model on the basis of the real TTRs in its warfarin-treated patients, with a fixed effect for country and random effect for center. For each patient, an individual TTR was also predicted with the use of a linear mixed effects model including patient characteristics as well. Median center average TTR was 66% (interquartile limits, 61% and 71%). Rates of stroke or systemic embolism, major bleeding, and mortality were consistently lower with apixaban than with warfarin across center average TTR and individual TTR quartiles. In the lowest and highest center average TTR quartiles, hazard ratios for stroke or systemic embolism were 0.73 (95% confidence interval [CI], 0.53–1.00) and 0.88 (95% CI, 0.57–1.35) (Pinteraction=0.078), for mortality were 0.91 (95% CI, 0.74–1.13) and 0.91 (95% CI, 0.71–1.16) (Pinteraction=0.34), and for major bleeding were 0.50 (95% CI, 0.36–0.70) and 0.75 (95% CI, 0.58–0.97) (Pinteraction=0.095), respectively. Similar results were seen for quartiles of individual TTR.ConclusionsThe benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control.Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.
  •  
129.
  •  
130.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 121-130 av 131
Typ av publikation
tidskriftsartikel (83)
konferensbidrag (41)
annan publikation (4)
bokkapitel (2)
rapport (1)
Typ av innehåll
refereegranskat (89)
övrigt vetenskapligt/konstnärligt (42)
Författare/redaktör
Steen, J (36)
Malmstrom, V (32)
KLARESKOG, L (20)
Espeseth, T (13)
Le Hellard, S (13)
Catrina, AI (13)
visa fler...
Gronwall, C. (12)
Palotie, A (12)
Djurovic, S (10)
Engstrom, M (10)
Andreassen, OA (9)
Corvin, A (9)
Rujescu, D (9)
Cichon, S (9)
Donohoe, G (9)
Ames, D (8)
Brodaty, H (8)
Thalamuthu, A (8)
Agartz, I (7)
Melle, I (7)
Breen, G (7)
Ehrlich, S (7)
Giddaluru, S (7)
Steen, VM (7)
Kennedy, J. (6)
Kaprio, J (6)
Kim, S. (6)
Schmidt, H. (6)
Westlye, LT (6)
Smith, T (6)
Johnson, R (6)
Chen, Q. (6)
Ophoff, RA (6)
Beretta, L (6)
Luciano, M (6)
Smith, C (6)
Seshadri, S (6)
Armstrong, NJ (6)
Crespo-Facorro, B (6)
Gudnason, V (6)
Heinz, A (6)
Jonsson, EG (6)
Reppermund, S (6)
Schmidt, R (6)
Schofield, PR (6)
Schumann, G (6)
McMurray, John J V (6)
Grill, V (6)
Murray, F (6)
Thomas, M (6)
visa färre...
Lärosäte
Karolinska Institutet (74)
Lunds universitet (22)
Uppsala universitet (17)
Göteborgs universitet (11)
Umeå universitet (10)
Stockholms universitet (7)
visa fler...
Kungliga Tekniska Högskolan (5)
Mälardalens universitet (5)
Örebro universitet (5)
Högskolan i Borås (4)
Högskolan Kristianstad (3)
Linköpings universitet (3)
Jönköping University (3)
Södertörns högskola (1)
Chalmers tekniska högskola (1)
RISE (1)
visa färre...
Språk
Engelska (128)
Svenska (2)
Italienska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (46)
Naturvetenskap (22)
Teknik (6)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy